Without a doubt, a cancer diagnosis is defined as a life-changing moment. Aside from making decisions regarding how treatment should be managed, it already has its challenges. Of course being a terminal diagnosis, it even becomes more complicated to make the right choices. But a Chicago-based company that deals with technology is committed to revolutionizing cancer treatment and management by creating systems that use personalized data to diagnose, and manage cancer.
Led by Eric Lefkofsky, Tempus was built in 2015 to enhance patient outcome. The organization is building one of the world’s most significant clinical data library of molecular systems to ensure that not only is data accessible but also useful for finding cancer treatment. It enables physicians to offer personalized care for patients with cancer through interactive analytical learning platforms. Moreover, the company ensures that data is available for patients, physicians, in addition to researchers.
Recently, Tempus received a round of funding worth $80 million from a team of investors. Since its establishment, the group has received about $210 million. The latest funding puts the organization’s value at $1.1 billion. This gives the firm a unicorn status. Coupled with about 400 employees, the organization is growing at an unbelievable rate. This pace will definitely continue especially with Eric Lefkofsky’s input as a leader.
Besides, Tempus provides a sequencing of DNA as well as RNA and proteomic services to generate high-quality molecular data as well as the therapeutic context to empower medical practitioners to come up with data-driven decisions.
Eric Lefkofsky’s Profile and Contribution
Eric Lefkofsky is an entrepreneur and philanthropist. He is the head of Tempus and has vast experience in management. An alumnus of the University of Chicago, Lefkofsky is committed to helping cancer patients come up with viable, informed decisions.